Post-shingles granulomatous dermatosis related to anti-programmed cell death 1

Tarek Assi; Alina Danu; Christine Mateus; Caroline Robert; Jean Marie Michot; Tony Ibrahim; Julien Lazarovici; David Ghez; Julien Rossignol; Peggy Dartigues; Marie Terroir-Cassou-Mounat; Vincent Ribrag

doi:10.2217/imt-2018-0169

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1

Tarek Assi, Alina Danu, Christine Mateus, Caroline Robert, Jean Marie Michot, Tony Ibrahim, Julien Lazarovici, David Ghez, Julien Rossignol, Peggy Dartigues, Marie Terroir-Cassou-Mounat, Vincent Ribrag

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

The most recent progress in the oncology field has led to a paradigm shift in the management of cancer with the tsunami of immune checkpoint inhibitors that are associated with a particular pattern of immunological adverse events. This is a case of a 54-year-old woman that demonstrated a granulomatous reaction in the same dermatomal distribution of a previously treated shingles infection during treatment with an anti-programmed death 1 agent (pembrolizumab) for a newly diagnosed stage IV Hodgkin lymphoma. The purpose of this case is to increase the awareness of oncologists dealing with a new pattern of side effects taking into account the patient's background and recent exposures to latent viruses such as herpes zoster to prevent unnecessary diagnostic and therapeutic measures.

Original language	English
Pages (from-to)	591-598
Number of pages	8
Journal	Immunotherapy
Volume	11
Issue number	7
DOIs	https://doi.org/10.2217/imt-2018-0169
Publication status	Published - 1 May 2019

Keywords

Hodgkin lymphoma
Immune granulomatosis
immune checkpoint inhibitors
pembrolizumab
shingles

Access to Document

10.2217/imt-2018-0169

Cite this

@article{da0278f55b6a4ae6a48ab70e531ef54c,

title = "Post-shingles granulomatous dermatosis related to anti-programmed cell death 1",

abstract = "The most recent progress in the oncology field has led to a paradigm shift in the management of cancer with the tsunami of immune checkpoint inhibitors that are associated with a particular pattern of immunological adverse events. This is a case of a 54-year-old woman that demonstrated a granulomatous reaction in the same dermatomal distribution of a previously treated shingles infection during treatment with an anti-programmed death 1 agent (pembrolizumab) for a newly diagnosed stage IV Hodgkin lymphoma. The purpose of this case is to increase the awareness of oncologists dealing with a new pattern of side effects taking into account the patient's background and recent exposures to latent viruses such as herpes zoster to prevent unnecessary diagnostic and therapeutic measures.",

keywords = "Hodgkin lymphoma, Immune granulomatosis, immune checkpoint inhibitors, pembrolizumab, shingles",

author = "Tarek Assi and Alina Danu and Christine Mateus and Caroline Robert and Michot, {Jean Marie} and Tony Ibrahim and Julien Lazarovici and David Ghez and Julien Rossignol and Peggy Dartigues and Marie Terroir-Cassou-Mounat and Vincent Ribrag",

note = "Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",

year = "2019",

month = may,

day = "1",

doi = "10.2217/imt-2018-0169",

language = "English",

volume = "11",

pages = "591--598",

journal = "Immunotherapy",

issn = "1750-743X",

number = "7",

}

TY - JOUR

T1 - Post-shingles granulomatous dermatosis related to anti-programmed cell death 1

AU - Assi, Tarek

AU - Danu, Alina

AU - Mateus, Christine

AU - Robert, Caroline

AU - Michot, Jean Marie

AU - Ibrahim, Tony

AU - Lazarovici, Julien

AU - Ghez, David

AU - Rossignol, Julien

AU - Dartigues, Peggy

AU - Terroir-Cassou-Mounat, Marie

AU - Ribrag, Vincent

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The most recent progress in the oncology field has led to a paradigm shift in the management of cancer with the tsunami of immune checkpoint inhibitors that are associated with a particular pattern of immunological adverse events. This is a case of a 54-year-old woman that demonstrated a granulomatous reaction in the same dermatomal distribution of a previously treated shingles infection during treatment with an anti-programmed death 1 agent (pembrolizumab) for a newly diagnosed stage IV Hodgkin lymphoma. The purpose of this case is to increase the awareness of oncologists dealing with a new pattern of side effects taking into account the patient's background and recent exposures to latent viruses such as herpes zoster to prevent unnecessary diagnostic and therapeutic measures.

AB - The most recent progress in the oncology field has led to a paradigm shift in the management of cancer with the tsunami of immune checkpoint inhibitors that are associated with a particular pattern of immunological adverse events. This is a case of a 54-year-old woman that demonstrated a granulomatous reaction in the same dermatomal distribution of a previously treated shingles infection during treatment with an anti-programmed death 1 agent (pembrolizumab) for a newly diagnosed stage IV Hodgkin lymphoma. The purpose of this case is to increase the awareness of oncologists dealing with a new pattern of side effects taking into account the patient's background and recent exposures to latent viruses such as herpes zoster to prevent unnecessary diagnostic and therapeutic measures.

KW - Hodgkin lymphoma

KW - Immune granulomatosis

KW - immune checkpoint inhibitors

KW - pembrolizumab

KW - shingles

UR - http://www.scopus.com/inward/record.url?scp=85063893457&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0169

DO - 10.2217/imt-2018-0169

M3 - Article

C2 - 30943861

AN - SCOPUS:85063893457

SN - 1750-743X

VL - 11

SP - 591

EP - 598

JO - Immunotherapy

JF - Immunotherapy

IS - 7

ER -

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1

Abstract

Keywords

Access to Document

Other files and links

Cite this